Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer

Prostate cancer is the most common nonskin malignancy among men in the United States. Since the introduction of screening with prostate-specific antigen (PSA), most patients are being diagnosed at an early stage with low-risk disease. For men with low-risk prostate cancer, there exists an array of r...

Full description

Bibliographic Details
Main Authors: Kevin S. Choe, Stanley L. Liauw
Format: Article
Language:English
Published: Hindawi Limited 2010-01-01
Series:The Scientific World Journal
Online Access:http://dx.doi.org/10.1100/tsw.2010.179
id doaj-cc3cea64ede34f27bc165886a8573d34
record_format Article
spelling doaj-cc3cea64ede34f27bc165886a8573d342020-11-25T00:08:39ZengHindawi LimitedThe Scientific World Journal1537-744X2010-01-01101854186910.1100/tsw.2010.179Radiotherapeutic Strategies in the Management of Low-Risk Prostate CancerKevin S. Choe0Stanley L. Liauw1Department of Radiation Oncology, University of Texas, Southwestern Medical Center, Dallas, TX, USADepartment of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, IL, USAProstate cancer is the most common nonskin malignancy among men in the United States. Since the introduction of screening with prostate-specific antigen (PSA), most patients are being diagnosed at an early stage with low-risk disease. For men with low-risk prostate cancer, there exists an array of radiotherapeutic strategies that are effective and well tolerated, such as external-beam radiotherapy and brachytherapy. In recent years, there have been tremendous advances in the field of radiation oncology that have transformed the way radiation is used to treat prostate cancer, such as intensity-modulated radiotherapy, image-guided radiotherapy, and stereotactic radiotherapy. It is now feasible to deliver high doses of radiation to the target volume with improved precision and spare more of the neighboring tissues from potentially damaging radiation. Disease outcomes are generally excellent in low-risk prostate cancer. Improvements are expected with further integration of innovative technologies in radiation delivery, tumor imaging, and target localization.http://dx.doi.org/10.1100/tsw.2010.179
collection DOAJ
language English
format Article
sources DOAJ
author Kevin S. Choe
Stanley L. Liauw
spellingShingle Kevin S. Choe
Stanley L. Liauw
Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer
The Scientific World Journal
author_facet Kevin S. Choe
Stanley L. Liauw
author_sort Kevin S. Choe
title Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer
title_short Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer
title_full Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer
title_fullStr Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer
title_full_unstemmed Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer
title_sort radiotherapeutic strategies in the management of low-risk prostate cancer
publisher Hindawi Limited
series The Scientific World Journal
issn 1537-744X
publishDate 2010-01-01
description Prostate cancer is the most common nonskin malignancy among men in the United States. Since the introduction of screening with prostate-specific antigen (PSA), most patients are being diagnosed at an early stage with low-risk disease. For men with low-risk prostate cancer, there exists an array of radiotherapeutic strategies that are effective and well tolerated, such as external-beam radiotherapy and brachytherapy. In recent years, there have been tremendous advances in the field of radiation oncology that have transformed the way radiation is used to treat prostate cancer, such as intensity-modulated radiotherapy, image-guided radiotherapy, and stereotactic radiotherapy. It is now feasible to deliver high doses of radiation to the target volume with improved precision and spare more of the neighboring tissues from potentially damaging radiation. Disease outcomes are generally excellent in low-risk prostate cancer. Improvements are expected with further integration of innovative technologies in radiation delivery, tumor imaging, and target localization.
url http://dx.doi.org/10.1100/tsw.2010.179
work_keys_str_mv AT kevinschoe radiotherapeuticstrategiesinthemanagementoflowriskprostatecancer
AT stanleylliauw radiotherapeuticstrategiesinthemanagementoflowriskprostatecancer
_version_ 1725415108498161664